IP Library Granted Patent US 10,150,784
Granted Patent B2
US 10,150,784 · App. 15/212,460 · Granted Dec 11, 2018

Crystal polymorph of magnesium glycinate dihydrate and process for its preparation

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,150,784
App. No.
15/212,460
Granted
Dec 11, 2018
Kind
B2
Abstract

Embodiments of the invention provide solid forms of magnesium glycinate dihydrate and compositions thereof, which are useful for treating hyperphosphatemia and which exhibit desirable characteristics for the same. The invention further provides processes for the production of solid forms of magnesium glycinate dihydrate.

Claims (10)

1. A process of manufacturing magnesium glycinate dihydrate comprising:

dissolving magnesium methoxide and glycine in methanol to provide a first solution;

heating the first solution at approximately 50-55° C. for at least 30 minutes;

adding water to the first solution to provide a second solution;

heating the second solution at approximately 50-55° C. for at least 30 minutes; and

cooling the second solution to approximately 25° C. or less.

2. The process of claim 1 , wherein magnesium glycinate dihydrate precipitates from the second solution.

3. The process of claim 1 , wherein magnesium glycinate dihydrate crystallizes from the second solution.

4. The process of claim 3 , further comprising isolating crystalline magnesium glycinate.

5. The process of claim 1 , wherein crystalline magnesium glycinate dihydrate is generated by removal of solvent from the second solution.

Assignments (3)
SECURITY INTEREST Recorded Dec 19, 2019
From: CURRAX PHARMACEUTICALS LLC; NALPROPION PHARMACEUTICALS LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB
Reel/Frame 051377/0958 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 31, 2019
From: CYPRESS PHRAMACEUTICALS, INC.
To: CURRAX PHARMACEUTICALS LLC
Reel/Frame 049329/0945 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 8, 2017
From: LEWIS, ROBERT
To: CYPRESS PHARMACEUTICALS, INC.
Reel/Frame 043226/0609 →